Glaxo Group Limited

Domantis Limited

Michael Steward

Alan Peter Lewis

Jonathan Henry Ellis

Ian M Tomlinson

Carolyn Enever

Paul Andrew Hamblin

Laurent S Jespers

Rudolf M T De Wildt

Stephanie Jane Clegg

Claire Ashman

Malgorzata Pupecka

Ian Richard Catchpole

Thil Dinuk Batuwangala

Peter Morley

Rudolf Maria De Wildt

Claire Holland

Farhana Hussain

Mary Birchler

Thomas Sandal

Zoe Hughes-Thomas

Michael Neil Burden

Martin Anibal Orecchia

Radha Shah

Thil Batuwangala

The present disclosure relates to modified proteins and peptides that have reduced ability to bind to pre-existing antibodies. Such modified protein/peptide molecules can comprise C-terminal additions, extensions or tags and/or certain amino acid substitutions. Such modified molecules (e.g., fusions and conjugates) comprise proteins, peptides, antigen binding molecules, antibodies or antibody fragments such as single variable domains. The disclosure further relates to uses and formulations of compositions comprising such modified C-terminally extended and/or amino acid substituted molecules and also to methods of production and expression of these.

Modified proteins and peptides

The present invention is directed to antigen binding constructs comprising one or two epitope binding domains separated by a single chain Fc region of an antibody, wherein each epitope binding domain in capable of binding to VEGF, to dimers comprising two antigen binding constructs of the invention, pharmaceutical compositions comprising said dimers and their use in the treatment of diseases associated with VEGF signalling, such as diabetic macular edema (DME), wet age-related macular degeneration (Wet AMD), diabetic retinopathy, retinal vein occlusion (RVO), and corneal neovascularization, and polynucleotide sequences encoding said antigen binding constructs.

Antigen binding constructs

The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.

Polypeptides, antibody variable domains and antagonists

Growing community of inventors

Stevenage, United Kingdom

Michael Steward